A CA 15-3 blood test measures a protein fragment shed into the bloodstream by certain cells, including many breast cancer cells. It is a tumor marker, and understanding what that phrase does not mean is the key to reading your result calmly: it is a tool for tracking a cancer that is already known about, not a test that finds one.
In this article you will learn what the marker is, why it is never used for screening, which harmless conditions raise it, how oncology teams read the trend rather than any single value, and what recent research says about newer blood tests that are beginning to complement it.
What a CA 15-3 blood test measures
CA stands for cancer antigen. The marker itself is a fragment of a large protein called mucin 1, which sits on the surface of many glandular cells and helps protect and lubricate the tissue. Breast tissue produces it normally. When breast cancer cells are present in significant numbers, they tend to produce far more of it and shed it into the blood, where it can be measured.
Because normal cells make the same protein, everyone has some in their bloodstream. The test result is therefore never simply present or absent; it is a concentration, reported in units per milliliter, and interpreted against a reference range that many laboratories set at roughly 0 to 30 U/mL.
The sample is an ordinary venous blood draw with no fasting requirement. Results usually take one to several days.
Why this test cannot screen for cancer
Two problems rule it out for screening. Many people with early breast cancer have a completely normal level, because small tumors do not shed enough of the protein to register. And many people with a raised level have no cancer at all, because benign conditions also raise it. A screening test needs to be reliable in both directions, and this one is not.
For that reason it is not recommended for anyone without a diagnosis, and a raised result in a healthy person is far more likely to reflect a benign cause than a hidden cancer. The same reasoning applies to related markers; see our CA 125 test results guide and our CEA blood test guide.
Why your doctor ordered this test
Almost always because a breast cancer diagnosis already exists and the team wants to follow it over time.
- Monitoring response to chemotherapy, hormone therapy or targeted treatment in advanced breast cancer.
- Watching for signs that a treated cancer has returned, in selected situations.
- Establishing a baseline at the start of treatment, so later values have something to be compared with.
- Occasionally helping to interpret an ambiguous scan finding in someone with known disease.
It is usually ordered alongside a broader panel. Liver and bone involvement can affect other results, which is why teams look at alkaline phosphatase levels, LDH blood test results and a complete blood count in the same visit.
How to read your CA 15-3 result
| Situation | What it usually means | What the team does |
|---|---|---|
| Within the reference range, no diagnosis | Expected; carries no information about cancer risk | Nothing |
| Mildly above the range, no diagnosis | Most often a benign cause such as liver or breast conditions | Repeat the test and look for a benign explanation |
| Falling across several tests during treatment | The treatment appears to be working | Continue the current plan |
| Rising steadily across several tests | Possible progression, but not proof of it | Imaging to check, before changing any treatment |
| A single unexpected jump | Often normal variation, an unrelated illness or a lab difference | Repeat before drawing conclusions |
Every row after the first depends on the same idea: this marker is read as a line on a graph, not as a single point. One value outside the reference range does not mean cancer is present or has returned.
The spike that is not what it looks like
Levels sometimes rise in the first weeks of a new treatment, even when that treatment is working. Dying tumor cells release their contents, including the marker. This transient rise is well recognized, and teams expect it, which is why an early increase after starting therapy is not treated as failure.
Results are also not comparable between laboratories. Different assays give different numbers for the same sample, so a change that looks alarming may simply reflect a change of lab. Keeping your testing in one place, where possible, makes the trend genuinely meaningful.
What raises CA 15-3 besides breast cancer
- Liver conditions, including hepatitis and cirrhosis, which are among the most common benign causes of a substantially raised level.
- Benign breast conditions such as fibroadenoma and mastitis.
- Endometriosis, ovarian cysts and pelvic inflammatory disease.
- Pregnancy and breastfeeding.
- Lung conditions including sarcoidosis and tuberculosis.
- Chronic kidney disease and some autoimmune conditions such as lupus.
- Other cancers, including lung, ovarian, pancreatic and colorectal, which can also produce the protein.
If a raised level appears alongside abnormal liver results, the liver is often the explanation. Compare with our ALT liver enzyme guide before assuming the worst.
When to talk to your doctor
- Bring any unexpected result to your oncology team rather than interpreting it alone. They have your previous values, your imaging and your treatment timeline, none of which appear on the report.
- Seek prompt review for new bone pain, persistent cough, breathlessness, unexplained weight loss or a new lump, regardless of what the marker shows. Symptoms outrank the number.
- Ask what your own baseline is if you are starting treatment, since a level of twenty means something different for someone whose baseline was ten than for someone whose baseline was sixty.
- Do not request this test as a general cancer check. A normal result would not be reassuring and a raised one would most likely be a false alarm.
It is also reasonable to ask why the test is being used at all. Not every breast cancer produces this marker, and if yours does not, following it adds anxiety without adding information. Teams often stop testing for exactly that reason. For the broader condition, see our overview of breast cancer symptoms, causes and treatments.
Latest scientific advances
The most interesting recent research is not about this marker itself but about what may sit alongside it. Here is what the past three years showed.
A trend-watching tool, not a yes or no test
A 2026 review of blood-based monitoring across several cancers concluded that markers like this one remain useful for tracking how a known cancer is responding over time, but are too imprecise for early detection and work best alongside newer DNA-based blood tests. What this means for you is a clear framing to hold on to. It is a trend-watching tool. A single value outside the reference range does not by itself mean the cancer is back.
Tumor DNA in blood can flag relapse much earlier
A 2026 multicenter trial followed eighty-three women with early breast cancer for five years using a personalized blood test that looks for fragments of the tumor’s own DNA. It flagged almost all relapses, typically around a year before the cancer appeared on scans. Circulating tumor DNA means small pieces of genetic material shed by cancer cells into the bloodstream. This is a promising approach, though what to do with such an early warning is still being studied.
A positive DNA result carries more weight than a wobbly marker
A 2024 study monitored sixty-one women at high risk of relapse. Every single patient whose blood showed tumor DNA during follow-up later relapsed, on average nearly a year afterwards. A negative result was less definitive, since some relapses were missed. The takeaway for a patient watching their own numbers is useful perspective: a fluctuating CA 15-3 is far less meaningful than a positive tumor DNA result, and if your team offers that kind of monitoring it is worth understanding what it can and cannot tell you.
None of this changes today’s practice. This marker is still interpreted as a trend, still confirmed with imaging before any treatment change, and still never used to screen people without a diagnosis.
Glossary
| Term | Definition |
|---|---|
| Tumor marker | A substance measurable in blood that can be produced in higher amounts by some cancers. |
| CA 15-3 | Cancer antigen 15-3, a fragment of the mucin 1 protein used mainly to monitor breast cancer. |
| Mucin 1 | A large protein on the surface of glandular cells, including normal breast cells. |
| U/mL | Units per milliliter, the measure used for this marker. |
| Baseline | Your own starting value, against which later results are compared. |
| CA 27-29 | A closely related breast cancer marker that measures the same underlying protein by a different method. |
| Circulating tumor DNA | Small fragments of genetic material shed by cancer cells into the bloodstream. |
| Progression | A cancer growing or spreading despite treatment. |
| False positive | A raised result in someone who does not have the condition the test is associated with. |
Frequently asked questions
What is a CA 15-3 blood test used for?
It is used to follow a breast cancer that has already been diagnosed, mainly to see whether treatment is working and to watch for signs of recurrence in selected situations. It is not used to detect cancer in people without a diagnosis, because many early cancers produce normal levels and many benign conditions produce raised ones. Your team reads the direction of change across several tests rather than any single value.
What is a normal CA 15-3 level?
Many laboratories use a reference range of roughly 0 to 30 U/mL, though the exact figure varies by assay, so read your value against the range on your own report. More important than the published range is your own baseline. A value of twenty-five means something different for a person whose previous results sat around ten than for someone whose results usually sit around fifty.
Does a high CA 15-3 mean my cancer has returned?
Not on its own. A single raised value can reflect normal test variation, a different laboratory, an unrelated illness, or a benign condition such as liver disease. Even in someone with a known cancer, a rising trend prompts imaging rather than an immediate change of treatment, because the scan is what confirms whether anything has actually changed. Discuss any unexpected result with your oncology team before drawing conclusions.
Can CA 15-3 be high without cancer?
Yes, and it is common. Liver conditions including hepatitis and cirrhosis, benign breast conditions, endometriosis, ovarian cysts, pregnancy, breastfeeding, lung conditions such as sarcoidosis, kidney disease and lupus can all raise it. This is one of the main reasons the test is not offered as a general cancer check: in someone without a diagnosis, a raised level is far more likely to have a benign explanation.
Why did my level rise just after starting treatment?
An early rise can happen precisely because the treatment is working. As tumor cells die they release their contents into the blood, including this marker, which can produce a temporary spike in the first weeks. Oncology teams recognize this pattern and do not treat it as failure. The value usually settles and then falls as treatment continues.
What is the difference between CA 15-3 and CA 27-29?
They measure the same underlying protein using different laboratory methods and different antibodies, so they give similar but not identical information. Which one your center uses depends on its laboratory. Because the numbers are not interchangeable, results should not be compared across the two tests, and switching between them mid-treatment makes the trend harder to interpret.
Sources
- National Cancer Institute — Tumor Marker Tests in Common Use — NCI Diagnosis and Staging, reviewed 2023 — cancer.gov
- MedlinePlus, National Library of Medicine — Tumor Marker Tests — MedlinePlus Medical Test, reviewed 2025 — medlineplus.gov
- Mayo Clinic Laboratories — Cancer Antigen 15-3 (CA 15-3), Serum: Test Overview — Mayo Clinic Laboratories Test Catalog — mayocliniclabs.com
- Connors LM, Rodriguez CS, et al — From Serum Markers to Liquid Biopsy: Precision Monitoring in Breast, Ovarian, Pancreatic, and Prostate Cancers — Seminars in Oncology Nursing, 2026 — doi.org/10.1016/j.soncn.2026.152167
- Blaye C, Bidard FC, et al — Tracking Structural Variants in Early Breast Cancer Using a High-Sensitivity ctDNA Assay Predicts Relapse in the Post-Neoadjuvant Setting: The Multicenter ALIENOR Trial — ESMO Open, 2026 — doi.org/10.1016/j.esmoop.2026.107766
- Garcia-Murillas I, Cutts RJ, et al — Longitudinal Monitoring of Circulating Tumor DNA to Detect Relapse Early and Predict Outcome in Early Breast Cancer — Breast Cancer Research and Treatment, 2024 — doi.org/10.1007/s10549-024-07508-2
Further reading
- Compare the marker used mainly in ovarian cancer monitoring with our CA 125 test results guide.
- Review the broader tumor marker used across several cancers in our CEA blood test guide.
- Understand the condition this marker follows by reading our breast cancer overview.
- Check the enzyme that can rise when cancer affects bone or liver using our alkaline phosphatase results guide.
- Explore the general marker of cell turnover often followed alongside it in our LDH blood test guide.
Understand your lab results with BloodSense
A tumor marker on a portal, without its history or context, is one of the most stressful numbers a person can encounter. BloodSense reads your full report and explains, in plain language, what this marker tracks, why the trend matters more than any single figure, and how your liver enzymes and blood count relate to it. It helps you prepare the right questions for your oncology team. It does not diagnose or stage cancer and never replaces your medical care.
